JP Morgan Chase’s Acceleron Pharma XLRN Stock Holding History

JP Morgan Chase’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-119,000	Closed	-$20.5M	–	7259
2021 Q3	$20.5M	Buy	+119,000	New	+$15.6M	﹤0.01%	1744
2020 Q3	–	Sell	-44,000	Closed	-$4.19M	–	5938
2020 Q2	$4.19M	Buy	+44,000	New	+$4.24M	﹤0.01%	2589
2019 Q3	–	Sell	-30,000	Closed	-$1.23M	–	6070
2019 Q2	$1.23M	Sell	30,000 -70,100	-70%	-$2.9M	﹤0.01%	3717
2019 Q1	$4.66M	Sell	100,100 -203,000	-67%	-$8.91M	﹤0.01%	2645
2018 Q4	$13.2M	Buy	303,100 +295,500	+3,888%	+$14.8M	﹤0.01%	1793
2018 Q3	$435K	Sell	7,600 -17,400	-70%	-$855K	﹤0.01%	4343
2018 Q2	$1.21M	Buy	+25,000	New	+$911K	﹤0.01%	3713

JP Morgan Chase's XLRN Position: Q4 2021 in Review

JP Morgan Chase sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 113,485 shares — an estimated $19.5M sold.

JP Morgan Chase first reported a position in XLRN in Q4 2013 and held it in 31 quarters. The position peaked at $40.9M in Q4 2015. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

JP Morgan Chase reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
JP Morgan Chase sold 113,485 Acceleron Pharma shares in Q4 2021, an estimated $19.5M.
JP Morgan Chase first reported a position in Acceleron Pharma in Q4 2013 and held it in 31 quarters.
JP Morgan Chase's Acceleron Pharma position peaked at $40.9M in Q4 2015.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on JP Morgan Chase's 13F filing for Q4 2021, filed 10 Feb 2022.